New therapeutic approach for the treatment for staphylococcal bacteremia and sepsis


Cite item

Full Text

Abstract

Introduction. Staphylococcal bacteremia is an early and dangerous manifestation of infection, it indicates to the presence of the source of infection in the bloodstream or the dissemination ofgerms from otherfoci, is the cause of high mortality rate. In that the approaches to the treatment for bacteremia/sepsis caused by S.aureus, have surprisingly low conclusiveness and require the optimization of antibiotic therapy, duration of treatment, criteria for cure. The aim of this study was to perform the systematic analysis of the current literature devoted to the problem of antibiotic treatment for staphylococcal infection, primarily followed by bacteremia and sepsis. Objectives of the study: the detection of the problem factors having the negative impact on the effectiveness of the antibiotic treatment of severe staphylococcal infections followed by bacteremia, and prospects for the use of new antibiotics. For the solution of the designated objectives in the scientific medical databases Medscape and Pubmed there was performed the search for the publications on subject headings, covering these problems Conclusion. Bacteremia and sepsis caused by S.aureus is not uncommon and severe infection which occurs everywhere, but remains to be poorly understood. The single isolation of S.aureus from the blood always is to be considered as clinically significant due to the high pathogenicity, high probability of infection and complications, rarity of contamination of blood samples with S.aureus. In cases of the isolation of staphylococci from the blood there is required an immediate and thorough search for any focus of invasion and deep metastatic foci of infection. There are strong evidences that the removal of the origin or the drainage of the locus of infection improves the results of the treatment. There is substantially less certainty about the patients with uncomplicated infections that can receive short courses of ABT. There is discussed the optimal choice of antibiotics, the duration and method of administration for the treatment of S. aureus bacteremia (SAB). Available data indicate to the more higher efficiency of f-lactams compared with glycopeptides for the treatment for infections caused by methicillin-sensitive SAB, the emergence of glycopeptide-intermediate Staphylococcus aureus (GISA) or hetero-GISA reduces the role of glycopeptides in the treatment of bacteremia caused by MRSA. Daptomycin showed the high efficacy in the treatment for severe staphylococcal infections accompanied by bacteremia and sepsis, especially when using in a dose of 6 mg/kg/ day and above. There is insufficient data for the assertion that cephalosporins are also effective as penicillins for treating SAB, but they are probably more effective than vancomycin for the treatment of methicillinsensitive SAB. The optimal duration of treatment is considered to be 10-14 days of intravenous administration for most cases of uncomplicated SAB associated with vascular catheterization, upon condition of the removal of the catheter and low risk of endocarditis.

About the authors

V. B Beloborodov

Russian Medical Academy of Postgraduate Education Studies

Email: vb_beloborodov@mail.ru
доктор мед. наук, проф. каф. инфекционных болезней 2/1, Barrikadnaya Str. , Moscow, Russian Federation, 125993

References

  1. Shorr A.F., Tabak Y.P., Killian A.D., Gupta V., Liu L.Z., Kollef M.H. Healthcare-associated bloodstream infection: a distinct entity? Insights from a large U.S. database. Crit Care Med 2006; 34: 2588-95.
  2. UK Health Protection Agency. Voluntary Reporting of Staphylococcus aureus bacteraemia in England, Wales, and Northern Ireland January-December 2008. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1258560519595 (accessed Nov 30, 2010).
  3. Wyllie D.H., Crook D.W., Peto T.E. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 19972003: cohort study. Br. Med. J. 2006; 333: 281.
  4. Грувер К.П., Белобородов В.Б. Клиническое значение бактериемии у больных сепсисом. Клиническая микробиология и антибактериальная химиотерапия. 2011; 13(1): 90-7.
  5. Liu C., Bayer A., Cosgrove S.E. et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clin. Infect. Dis. 2011; 52: 1-38.
  6. Naber C.K., Baddour L.M., Giamarellos-Bourboulis E.J. et al. Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus. Clin. Infect. Dis. 2009; 48 (Suppl. 4): S. 260.
  7. Khatib R., Johnson L.B., Fakih M.G. et al. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand. J. Infect. Dis. 2006; 38: 7-14.
  8. Wilson R., Hamburger M. Fifteen years’ experience with Staphylococcus septicemia in a large city hospital; analysis of fifty-five cases in the Cincinnati General Hospital 1940 to 1954. Am. J. Med. 1957; 22: 437-57.
  9. Fernandez Guerrero M.L., Gonzalez Lopez J.J., Goyenechea A., Fraile J., de Gorgolas M. Endocarditis caused by Staphylococcus aureus: a reappraisal of the epidemiologic, clinical, and pathologic manifestations with analysis of factors determining outcome. Medicine (Baltimore). 2009; 88: 1-22.
  10. Chang F.Y., Mac Donald B.B., Peacock J.E. Jr. et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore). 2003; 82: 322-32.
  11. Van Hal S.J., Mathur G., Kelly J., Aronis C., Cranney G.B., Jones P.D. The role of transthoracic echocardiography in excluding left sided infective endocarditis in Staphylococcus aureus bacteraemia. J. Infect. 2005; 51: 218-21.
  12. Evangelista A., Gonzalez-Alujas M.T. Echocardiography in infective endocarditis. Heart. 2004; 90: 614-7.
  13. Fortun J., Navas E., Martinez-Beltran J., et al. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin. Infect. Dis. 2001; 33: 120-5.
  14. Khatib R., Johnson L.B., Sharma M., Fakih M.G., Ganga R., Riederer K. Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time. Scand. J. Infect. Dis. 2009; 41: 4-9.
  15. Lodise T.P. Jr., McKinnon P.S., Levine D.P., Rybak M.J. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 2007; 51: 3731-3.
  16. Appelbaum P.C. Reduced glycopeptide susceptibility inmethicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents. 2007; 30: 398-408.
  17. Rybak M.J., Leonard S.N., Rossi K.L., Cheung C.M., Sader H.S., Jones R.N. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J. Clin. Microbiol. 2008; 46: 2950-4.
  18. Lodise T.P., Graves J., Evans A., et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 2008; 52: 3315-20.
  19. Chambers H.F., Mills J., Drake T.A., Sande M.A. Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus. Rev. Infect. Dis. 1984; 6 (Suppl. 4): S870-4.
  20. Nannini E.C., Stryjewski M.E., Singh K.V. et al. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob Agents Chemother. 2009; 53: 3437-41.
  21. Fujii R. Experience with cefotaxime in infections caused by Gram-positive pathogens, especially Staphylococcus aureus. Infection. 1985; 13 (Suppl. 1): S9-13.
  22. Soriano E., Gatell J.M., Aguado J.M. et al. Ceftriaxone monotherapy for severe bacteremic infections. Chemotherapy. 1989; 35 (Suppl. 2): 27-32.
  23. Rahal J.J.Jr., Chan Y.K., Johnson G. Relationship of staphylococcal tolerance, teichoic acid antibody, and serum bactericidal activity to therapeutic outcome in Staphylococcus aureus bacteremia. Am. J. Med. 1986; 81: 43-52.
  24. Zeylemaker M.M., Jaspers C.A., van Kraaij M.G., Visser M.R., Hoepelman I.M. Long-term infectious complications and their relation to treatment duration in catheter-related Staphylococcus aureus bacteremia. Eur. J. Clin. Microbiol. Infect. Dis. 2001; 20: 380-4.
  25. Malanoski G.J., Samore M.H., Pefanis A., Karchmer A.W. Staphylococcus aureus catheter-associated bacteremia. Minimal effective therapy and unusual infectious complications associated with arterial sheath catheters. Arch. Intern. Med. 1995; 155: 1161-66.
  26. Ghanem G.A., Boktour M., Warneke C. et al. Catheter-related Staphylococcus aureus bacteremia in cancer patients: high rate of complications with therapeutic implications. Medicine (Baltimore). 2007; 86: 54-60.
  27. Torres-Tortosa M., de Cueto M., Vergara A. et al. Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis. Eur. J. Clin. Microbiol. Infect. Dis. 1994; 13: 559-64.
  28. Falagas M.E., Matthaiou D.K., Bliziotis I.A. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J. Antimicrob. Chemother. 2006; 57: 639-47.
  29. Cosgrove S.E., Vigliani G.A., Fowler V.G. Jr. et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin. Infect. Dis. 2009; 48: 713-21.
  30. Ruotsalainen E., Jarvinen A., Koivula I. et al. Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients. J. Intern. Med. 2006; 259: 179-90.
  31. Gransden W.R., Eykyn S.J., Phillips I. Staphylococcus aureus bacteraemia: 400 episodes in St Thomas’s Hospital. Br. Med. J. 1984; 288: 300-03.
  32. Huang Y.T., Hsiao C.H., Liao C.H., Lee C.W., Hsueh P.R. Bacteremia and infective endocarditis caused by a nondaptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. J. Clin. Microbiol. 2008; 46: 1132-36.
  33. Howden B.P., Ward P.B., Charles P.G. et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 2004; 38: 521-8.
  34. Whitby M. Fusidic acid in septicaemia and endocarditis. Int. J. Antimicrob. Agents. 1999; 12 (Suppl. 2): S17-22.
  35. Shorr A.F., Kunkel M.J., Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J. Antimicrob. Chemother. 2005; 56: 923-9.
  36. Falagas M.E., Siempos I.I., Vardakas K.Z. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet. Infect. Dis. 2008; 8: 53-66.
  37. Falagas M.E., Manta K.G., Ntziora F., Vardakas K.Z. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J. Antimicrob. Chemother. 2006; 58: 273-80.
  38. Wilcox M.H., Tack K.J., Bouza E. et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin. Infect. Dis. 2009; 48: 203-12.
  39. Jang H.C., Kim S.H., Kim K.H. et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin. Infect. Dis. 2009; 49: 395-401.
  40. Fowler V.G.Jr., Boucher H.W., Corey G.R. et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 2006; 355: 653-65.
  41. Sakoulas G., Brown J., Lamp K.C., Friedrich L.V., Lindfield K.C. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. Clin. Ther. 2009; 31: 1936-45.
  42. Falagas M.E., Giannopoulou K.P., Ntziora F., Vardakas K.Z. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J. Antimicrob. Chemother. 2007; 60: 7-19.
  43. Falagas M.E., Giannopoulou K.P., Ntziora F., Papagelopoulos P.J. Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. Int. J. Antimicrob. Agents. 2007; 30: 202-9.
  44. Sharma M., Riederer K., Chase P., Khatib R. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur. J. Clin. Microbiol. Infect. Dis. 2008; 27: 433-7.
  45. Sakoulas G. Clinical outcomes with daptomycin: a post-marketing, real-world evaluation. Clin. Microbiol. Infect. 2009; 15 (Suppl. 6): 11-6.
  46. Sakoulas G., Alder J., Thauvin-Eliopoulos C., Moellering R.C.Jr., Eliopoulos G.M. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 2006; 50: 1581-5.
  47. Rose W.E., Leonard S.N., Sakoulas G. et al. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 2008; 52: 831-6.
  48. Cui L., Tominaga E., Neoh H.M., Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 2006; 50: 1079-82.
  49. Sader H.S., Fritsche T.R., Jones R.N. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob. Agents Chemother. 2006; 50: 2330-6.
  50. Moise P.A., Hershberger E., Amodio-Groton M.I., Lamp K.C. Safety and clinical outcomes when utilizing high-dose (> or = 8 mg/kg) daptomycin therapy. Ann Pharmacother. 2009; 43: 1211-9.
  51. Rose W.E., Rybak M.J., Kaatz G.W. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J. Antimicrob. Chemother. 2007; 60: 334-40.
  52. Benvenuto M., Benziger D.P., Yankelev S., Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 2006; 50: 3245-49.
  53. Dohmen P. et al. 22th (2012) European Congressof Clinical Microbiology and Infectious Diseases. Poster; 1844.
  54. Dohmen P. et al. 22th (2012) European Congressof Clinical Microbiology and Infectious Diseases. Poster; 1845.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2014 Eco-vector


 


Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».